Latest Breaking News On - Ev 302 study - Page 1 : comparemela.com

Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.

Sia daneshmandRadical cystectomyMetastatic diseaseChemo radiationPlatinum based therapiesEv 302 studyOpen labelRandomized studyEnfortumab vedotin in combinationPlatinum based therapyStandard of careFirst line setting